Related Experiment Video
Updated: Dec 19, 2025
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.2K
Advanced papillary thyroid carcinoma responding to nivolumab
Miguel Michel Ocampo1, Jaren Lerner1, Shawnt Tosonian1
1Department of Internal Medicine, Eisenhower Health, Rancho Mirage, CA, USA.
Summary
This case study shows nivolumab, a programmed death 1 inhibitor, effectively treated both metastatic hepatocellular carcinoma and papillary thyroid carcinoma. This offers new hope for patients with these rare synchronous malignancies.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Immune checkpoint inhibitors (ICIs) like nivolumab and pembrolizumab are increasingly used for various cancers.
- Programmed death 1 (PD-1) inhibitors show response rates of about 16% in hepatocellular carcinoma (HCC).
Observation:
- A patient with synchronous metastatic HCC and advanced papillary thyroid carcinoma (PTC) received second-line nivolumab therapy.
- The patient experienced a durable response in their HCC.
- Notably, the patient's PTC also demonstrated a positive response to nivolumab.
Findings:
- This is the first reported case of nivolumab showing efficacy in metastatic papillary thyroid carcinoma.
- Nivolumab provided a durable response for advanced hepatocellular carcinoma.
- The study highlights the potential of PD-1 inhibition in treating both HCC and PTC.
Implications:
- These findings suggest that nivolumab may be an effective treatment option for papillary thyroid carcinoma.
- Further clinical investigations into the use of immune checkpoint inhibitors for PTC are warranted.
- This case broadens the understanding of ICI efficacy in rare synchronous malignancies.
Related Concept Videos
01:27Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K